Welcome to Today's Virtual Symposium for Investors and Analysts
The presentations today include forward-looking statements of IVERIC bio, Inc. (the "Company"). Any statements about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company's strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "future", "may", "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. In the presentations today, the Company's forward looking statements include statements about the timing, progress and results of clinical trials, including expectations regarding patient enrollment and retention in GATHER2, the Company's development strategy for Zimura and IC-500, including their potential development in other forms or stages of dry age-related macular degeneration, the Company's hypotheses regarding complement inhibition and inhibition of HtrA1 as mechanisms of action to treat GA and other forms of dry AMD, estimates regarding the number of patients the Company's product candidates are intended to treat, and the utility of Zimura and IC-500. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and
uncertainties include, among others, those related to the progression and duration of the COVID-19 pandemic and responsive
measures thereto and related effects on the Company's research and development programs, operations and financial position, the initiation and the progress of research and development programs and clinical trials, availability of data from these programs, expectations for regulatory matters, reliance on clinical trial sites, contract research organizations and other third parties, developments from the Company's competitors and the marketplace for its products, need for additional financing and negotiation and consummation of business development transactions and other factors discussed in the "Risk Factors" section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company's views only as of today. The Company anticipates that subsequent events and developments may cause its views to
change. While the Company may elect to update these forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so except as required by law.